Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below ...

The firms entered into a merger agreement in February for Novo Holdings to acquire Catalent in an all-cash transaction worth $16.5 billion. That deal still expects to close toward the end of ...

After our most recent round of testing, we have two new picks: the Nextmug and the Mr. Coffee Mug Warmer. November 2024 The second your coffee machine or kettle finishes its work, you have only so ...

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ...

They’re also more convenient — I make my coffee and tea at home the vast majority of the time, but now, I pour it into one of the few reusable mugs I tested for this story whenever I want to ...

Investors eyeing a purchase of Catalent Inc (Symbol: CTLT) stock, but tentative about paying the going market price of $59.14/share, might benefit from considering selling puts among the ...

Update 12:30pm: Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Holdings to purchase Catalent ...

Catalent and Ardena did not disclose financial terms of the deal, which is expected to close in early 2025. Ardena, a ...

At the same time, Catalent is one of the “very few” contract drug manufacturers that provides specialized development and manufacturing services to companies that sell these medicines.

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50. David Windley has given his Hold rating due to a combination ...

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per ...

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a ...